2023-2029 Global Benign Prostatic Hyperplasia Drugs Industry Research & Trends Analysis Report
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
According to the research report, the global market for Benign Prostatic Hyperplasia Drugs should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
China Benign Prostatic Hyperplasia Drugs market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
The United States Benign Prostatic Hyperplasia Drugs market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
In terms of type, Tamsulosin segment holds a share about % in 2022 and will reach % in 2029; while in terms of application, Hospital has a share approximately % in 2022 and will grow at a CAGR % during 2023 and 2029.
The global key manufacturers of Benign Prostatic Hyperplasia Drugs include Sanofi, Boehringer Ingelheim, Maithili Life Sciences, DM Pharma, Teva Pharmaceuticals, Mylan, Zydus Pharmaceuticals, Wockhardt and Sun Pharmaceutical, etc. In 2022, the global top five players hold a share approximately % in terms of revenue.
This report aims to provide a comprehensive study of the global market for Benign Prostatic Hyperplasia Drugs. Report Highlights:
(1) Global Benign Prostatic Hyperplasia Drugs market size (value), history data from 2018-2022 and forecast data from 2023 to 2029.
(2) Global Benign Prostatic Hyperplasia Drugs market competitive situation, revenue and market share, from 2018 to 2022.
(3) China Benign Prostatic Hyperplasia Drugs market competitive situation, revenue and market share, from 2018 to 2022.
(4) Global Benign Prostatic Hyperplasia Drugs segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.
(5) Global Benign Prostatic Hyperplasia Drugs segment by type and by application and regional segment by type and by application.
(6) Benign Prostatic Hyperplasia Drugs industry supply chain, upstream, midstream and downstream analysis.
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by type, covers
Tamsulosin
Finasteride
Terazosin
Other
Market segment by application, can be divided into
Hospital
Clinic
Other
Market segment by players, this report covers
Sanofi
Boehringer Ingelheim
Maithili Life Sciences
DM Pharma
Teva Pharmaceuticals
Mylan
Zydus Pharmaceuticals
Wockhardt
Sun Pharmaceutical
Glenmark Pharmaceuticals Ltd.
TRB Pharma S.A.
Kunming Jida Pharmaceutical Co., Ltd.
Medzeel Lifescience
Wellona Pharma
Niksan Pharmaceutical
Lunan Pharmaceutical Group Corporation
Zhejiang Xianju Pharmaceutical Co.,Ltd.
Hunan Jiudian Pharmaceutical Co.,Ltd.
Chengdu Brilliant Pharmaceutical Co., Ltd.
Guangdong Eashu Pharmaceutical Co.,Ltd.
1 Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia Drugs
1.2 Global Benign Prostatic Hyperplasia Drugs Market Size and Forecast
1.3 China Benign Prostatic Hyperplasia Drugs Market Size and Forecast
1.4 China Market Percentage in Global
1.4.1 By Revenue, China Benign Prostatic Hyperplasia Drugs Share in Global Market, 2018-2029
1.4.2 Benign Prostatic Hyperplasia Drugs Market Size: China VS Global, 2018-2029
1.5 Benign Prostatic Hyperplasia Drugs Market Dynamics
1.5.1 Benign Prostatic Hyperplasia Drugs Market Drivers
1.5.2 Benign Prostatic Hyperplasia Drugs Market Restraints
1.5.3 Benign Prostatic Hyperplasia Drugs Industry Trends
1.5.4 Benign Prostatic Hyperplasia Drugs Industry Policy
2 Global Competitive Situation by Company
2.1 Global Benign Prostatic Hyperplasia Drugs Revenue by Company (2018-2023)
2.2 Global Benign Prostatic Hyperplasia Drugs Participants, Market Position (Tier 1, Tier 2 and Tier 3)
2.3 Global Benign Prostatic Hyperplasia Drugs Concentration Ratio
2.4 Global Benign Prostatic Hyperplasia Drugs Mergers & Acquisitions, Expansion Plans
2.5 Global Benign Prostatic Hyperplasia Drugs Manufacturers Product Type
3 China Competitive Situation by Company
3.1 China Benign Prostatic Hyperplasia Drugs Revenue by Company (2018-2023)
3.2 China Benign Prostatic Hyperplasia Drugs Benign Prostatic Hyperplasia Drugs Participants, Market Position (Tier 1, Tier 2 and Tier 3)
3.3 China Benign Prostatic Hyperplasia Drugs, Revenue Percentage of Local Players VS Foreign Manufacturers (2018-2023)
4 Industry Chain Analysis
4.1 Benign Prostatic Hyperplasia Drugs Industry Chain
4.2 Benign Prostatic Hyperplasia Drugs Upstream Analysis
4.3 Benign Prostatic Hyperplasia Drugs Midstream Analysis
4.4 Benign Prostatic Hyperplasia Drugs Downstream Analysis
5 Sights by Type
5.1 Benign Prostatic Hyperplasia Drugs Classification
5.1.1 Tamsulosin
5.1.2 Finasteride
5.1.3 Terazosin
5.1.4 Other
5.2 By Type, Global Benign Prostatic Hyperplasia Drugs Market Size & CAGR, 2018 VS 2022 VS 2029
5.3 By Type, Global Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029
6 Sights by Application
6.1 Benign Prostatic Hyperplasia Drugs Segment by Application
6.1.1 Hospital
6.1.2 Clinic
6.1.3 Other
6.2 By Application, Global Benign Prostatic Hyperplasia Drugs Market Size & CAGR, 2018 VS 2022 VS 2029
6.3 By Application, Global Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029
7 Sales Sights by Region
7.1 By Region, Global Benign Prostatic Hyperplasia Drugs Market Size, 2018 VS 2022 VS 2029
7.2 By Region, Global Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
7.3 North America
7.3.1 North America Benign Prostatic Hyperplasia Drugs Market Size & Forecasts, 2018-2029
7.3.2 By Country, North America Benign Prostatic Hyperplasia Drugs Market Size Market Share
7.4 Europe
7.4.1 Europe Benign Prostatic Hyperplasia Drugs Market Size & Forecasts, 2018-2029
7.4.2 By Country, Europe Benign Prostatic Hyperplasia Drugs Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Benign Prostatic Hyperplasia Drugs Market Size & Forecasts, 2018-2029
7.5.2 By Country/Region, Asia Pacific Benign Prostatic Hyperplasia Drugs Market Size Market Share
7.6 South America
7.6.1 South America Benign Prostatic Hyperplasia Drugs Market Size & Forecasts, 2018-2029
7.6.2 By Country, South America Benign Prostatic Hyperplasia Drugs Market Size Market Share
7.7 Middle East & Africa
8 Sights by Country Level
8.1 By Country, Global Benign Prostatic Hyperplasia Drugs Market Size & CAGR，2018 VS 2022 VS 2029
8.2 By Country, Global Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
8.3 U.S.
8.3.1 U.S. Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
8.3.2 By Company, U.S. Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2023
8.3.3 By Type, U.S. Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.3.4 By Application, U.S. Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.4 Europe
8.4.1 Europe Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
8.4.2 By Company, Europe Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2023
8.4.3 By Type, Europe Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.4.4 By Application, Europe Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.5 China
8.5.1 China Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
8.5.2 By Company, China Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2023
8.5.3 By Type, China Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.5.4 By Application, China Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.6 Japan
8.6.1 Japan Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
8.6.2 By Company, Japan Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2023
8.6.3 By Type, Japan Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.6.4 By Application, Japan Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.7 South Korea
8.7.1 South Korea Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
8.7.2 By Company, South Korea Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2023
8.7.3 By Type, South Korea Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.7.4 By Application, South Korea Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.8 Southeast Asia
8.8.1 Southeast Asia Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
8.8.2 By Company, Southeast Asia Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2023
8.8.3 By Type, Southeast Asia Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.8.4 By Application, Southeast Asia Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.9 India
8.9.1 India Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
8.9.2 By Company, India Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2023
8.9.3 By Type, India Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.9.4 By Application, India Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.10 Middle East & Asia
8.10.1 Middle East & Asia Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
8.10.2 By Company, Middle East & Asia Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2023
8.10.3 By Type, Middle East & Asia Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
8.10.4 By Application, Middle East & Asia Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
9 Global Manufacturers Profile
9.1 Sanofi
9.1.1 Sanofi Company Information, Head Office, Market Area and Industry Position
9.1.2 Sanofi Company Profile and Main Business
9.1.3 Sanofi Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.1.4 Sanofi Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.1.5 Sanofi Recent Developments
9.2 Boehringer Ingelheim
9.2.1 Boehringer Ingelheim Company Information, Head Office, Market Area and Industry Position
9.2.2 Boehringer Ingelheim Company Profile and Main Business
9.2.3 Boehringer Ingelheim Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.2.4 Boehringer Ingelheim Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.2.5 Boehringer Ingelheim Recent Developments
9.3 Maithili Life Sciences
9.3.1 Maithili Life Sciences Company Information, Head Office, Market Area and Industry Position
9.3.2 Maithili Life Sciences Company Profile and Main Business
9.3.3 Maithili Life Sciences Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.3.4 Maithili Life Sciences Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.3.5 Maithili Life Sciences Recent Developments
9.4 DM Pharma
9.4.1 DM Pharma Company Information, Head Office, Market Area and Industry Position
9.4.2 DM Pharma Company Profile and Main Business
9.4.3 DM Pharma Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.4.4 DM Pharma Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.4.5 DM Pharma Recent Developments
9.5 Teva Pharmaceuticals
9.5.1 Teva Pharmaceuticals Company Information, Head Office, Market Area and Industry Position
9.5.2 Teva Pharmaceuticals Company Profile and Main Business
9.5.3 Teva Pharmaceuticals Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.5.4 Teva Pharmaceuticals Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.5.5 Teva Pharmaceuticals Recent Developments
9.6 Mylan
9.6.1 Mylan Company Information, Head Office, Market Area and Industry Position
9.6.2 Mylan Company Profile and Main Business
9.6.3 Mylan Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.6.4 Mylan Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.6.5 Mylan Recent Developments
9.7 Zydus Pharmaceuticals
9.7.1 Zydus Pharmaceuticals Company Information, Head Office, Market Area and Industry Position
9.7.2 Zydus Pharmaceuticals Company Profile and Main Business
9.7.3 Zydus Pharmaceuticals Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.7.4 Zydus Pharmaceuticals Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.7.5 Zydus Pharmaceuticals Recent Developments
9.8 Wockhardt
9.8.1 Wockhardt Company Information, Head Office, Market Area and Industry Position
9.8.2 Wockhardt Company Profile and Main Business
9.8.3 Wockhardt Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.8.4 Wockhardt Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.8.5 Wockhardt Recent Developments
9.9 Sun Pharmaceutical
9.9.1 Sun Pharmaceutical Company Information, Head Office, Market Area and Industry Position
9.9.2 Sun Pharmaceutical Company Profile and Main Business
9.9.3 Sun Pharmaceutical Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.9.4 Sun Pharmaceutical Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.9.5 Sun Pharmaceutical Recent Developments
9.10 Glenmark Pharmaceuticals Ltd.
9.10.1 Glenmark Pharmaceuticals Ltd. Company Information, Head Office, Market Area and Industry Position
9.10.2 Glenmark Pharmaceuticals Ltd. Company Profile and Main Business
9.10.3 Glenmark Pharmaceuticals Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.10.4 Glenmark Pharmaceuticals Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.10.5 Glenmark Pharmaceuticals Ltd. Recent Developments
9.11 TRB Pharma S.A.
9.11.1 TRB Pharma S.A. Company Information, Head Office, Market Area and Industry Position
9.11.2 TRB Pharma S.A. Company Profile and Main Business
9.11.3 TRB Pharma S.A. Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.11.4 TRB Pharma S.A. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.11.5 TRB Pharma S.A. Recent Developments
9.12 Kunming Jida Pharmaceutical Co., Ltd.
9.12.1 Kunming Jida Pharmaceutical Co., Ltd. Company Information, Head Office, Market Area and Industry Position
9.12.2 Kunming Jida Pharmaceutical Co., Ltd. Company Profile and Main Business
9.12.3 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.12.4 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.12.5 Kunming Jida Pharmaceutical Co., Ltd. Recent Developments
9.13 Medzeel Lifescience
9.13.1 Medzeel Lifescience Company Information, Head Office, Market Area and Industry Position
9.13.2 Medzeel Lifescience Company Profile and Main Business
9.13.3 Medzeel Lifescience Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.13.4 Medzeel Lifescience Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.13.5 Medzeel Lifescience Recent Developments
9.14 Wellona Pharma
9.14.1 Wellona Pharma Company Information, Head Office, Market Area and Industry Position
9.14.2 Wellona Pharma Company Profile and Main Business
9.14.3 Wellona Pharma Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.14.4 Wellona Pharma Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.14.5 Wellona Pharma Recent Developments
9.15 Niksan Pharmaceutical
9.15.1 Niksan Pharmaceutical Company Information, Head Office, Market Area and Industry Position
9.15.2 Niksan Pharmaceutical Company Profile and Main Business
9.15.3 Niksan Pharmaceutical Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.15.4 Niksan Pharmaceutical Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.15.5 Niksan Pharmaceutical Recent Developments
9.16 Lunan Pharmaceutical Group Corporation
9.16.1 Lunan Pharmaceutical Group Corporation Company Information, Head Office, Market Area and Industry Position
9.16.2 Lunan Pharmaceutical Group Corporation Company Profile and Main Business
9.16.3 Lunan Pharmaceutical Group Corporation Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.16.4 Lunan Pharmaceutical Group Corporation Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.16.5 Lunan Pharmaceutical Group Corporation Recent Developments
9.17 Zhejiang Xianju Pharmaceutical Co.,Ltd.
9.17.1 Zhejiang Xianju Pharmaceutical Co.,Ltd. Company Information, Head Office, Market Area and Industry Position
9.17.2 Zhejiang Xianju Pharmaceutical Co.,Ltd. Company Profile and Main Business
9.17.3 Zhejiang Xianju Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.17.4 Zhejiang Xianju Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.17.5 Zhejiang Xianju Pharmaceutical Co.,Ltd. Recent Developments
9.18 Hunan Jiudian Pharmaceutical Co.,Ltd.
9.18.1 Hunan Jiudian Pharmaceutical Co.,Ltd. Company Information, Head Office, Market Area and Industry Position
9.18.2 Hunan Jiudian Pharmaceutical Co.,Ltd. Company Profile and Main Business
9.18.3 Hunan Jiudian Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.18.4 Hunan Jiudian Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.18.5 Hunan Jiudian Pharmaceutical Co.,Ltd. Recent Developments
9.19 Chengdu Brilliant Pharmaceutical Co., Ltd.
9.19.1 Chengdu Brilliant Pharmaceutical Co., Ltd. Company Information, Head Office, Market Area and Industry Position
9.19.2 Chengdu Brilliant Pharmaceutical Co., Ltd. Company Profile and Main Business
9.19.3 Chengdu Brilliant Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.19.4 Chengdu Brilliant Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.19.5 Chengdu Brilliant Pharmaceutical Co., Ltd. Recent Developments
9.20 Guangdong Eashu Pharmaceutical Co.,Ltd.
9.20.1 Guangdong Eashu Pharmaceutical Co.,Ltd. Company Information, Head Office, Market Area and Industry Position
9.20.2 Guangdong Eashu Pharmaceutical Co.,Ltd. Company Profile and Main Business
9.20.3 Guangdong Eashu Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
9.20.4 Guangdong Eashu Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
9.20.5 Guangdong Eashu Pharmaceutical Co.,Ltd. Recent Developments
10 Conclusion
11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer
Tables & Figures:
Table 1. Benign Prostatic Hyperplasia Drugs Market Size & CAGR: China VS Global, (US$ Million), 2018-2029
Table 2. Benign Prostatic Hyperplasia Drugs Market Restraints
Table 3. Benign Prostatic Hyperplasia Drugs Market Trends
Table 4. Benign Prostatic Hyperplasia Drugs Industry Policy
Table 5. Global Benign Prostatic Hyperplasia Drugs Revenue by Company (2018-2023) & (US$ million)
Table 6. Global Benign Prostatic Hyperplasia Drugs Revenue Market Share by Company (2018-2023)
Table 7. Global Benign Prostatic Hyperplasia Drugs Manufacturers Market Concentration Ratio (CR3 and HHI)
Table 8. Global Benign Prostatic Hyperplasia Drugs Mergers & Acquisitions, Expansion Plans
Table 9. Global Benign Prostatic Hyperplasia Drugs Manufacturers Product Type
Table 10. China Benign Prostatic Hyperplasia Drugs Revenue by Company (2018-2023) & (US$ million)
Table 11. China Benign Prostatic Hyperplasia Drugs Revenue Market Share by Company (2018-2023)
Table 12. Global Key Players of Benign Prostatic Hyperplasia Drugs Upstream (Raw Materials)
Table 13. Global Benign Prostatic Hyperplasia Drugs Typical Customers
Table 14. Benign Prostatic Hyperplasia Drugs Typical Distributors
Table 15. By Type, Global Benign Prostatic Hyperplasia Drugs Revenue & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 16. By Application, Global Benign Prostatic Hyperplasia Drugs Revenue & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 17. By Region, Global Benign Prostatic Hyperplasia Drugs Market Size, 2018 VS 2022 VS 2029, US$ Million
Table 18. By Region, Global Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029, US$ Million
Table 19. By Country, Global Benign Prostatic Hyperplasia Drugs Revenue & CAGR，2018 VS 2022 VS 2029, US$ Million
Table 20. By Country, Global Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029, US$ Million
Table 21. By Country, Global Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2029
Table 22. Sanofi Company Information, Head Office, Market Area and Industry Position
Table 23. Sanofi Company Profile and Main Business
Table 24. Sanofi Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 25. Sanofi Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 26. Sanofi Recent Developments
Table 27. Boehringer Ingelheim Company Information, Head Office, Market Area and Industry Position
Table 28. Boehringer Ingelheim Company Profile and Main Business
Table 29. Boehringer Ingelheim Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 30. Boehringer Ingelheim Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 31. Boehringer Ingelheim Recent Developments
Table 32. Maithili Life Sciences Company Information, Head Office, Market Area and Industry Position
Table 33. Maithili Life Sciences Company Profile and Main Business
Table 34. Maithili Life Sciences Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 35. Maithili Life Sciences Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 36. Maithili Life Sciences Recent Developments
Table 37. DM Pharma Company Information, Head Office, Market Area and Industry Position
Table 38. DM Pharma Company Profile and Main Business
Table 39. DM Pharma Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 40. DM Pharma Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 41. DM Pharma Recent Developments
Table 42. Teva Pharmaceuticals Company Information, Head Office, Market Area and Industry Position
Table 43. Teva Pharmaceuticals Company Profile and Main Business
Table 44. Teva Pharmaceuticals Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 45. Teva Pharmaceuticals Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 46. Teva Pharmaceuticals Recent Developments
Table 47. Mylan Company Information, Head Office, Market Area and Industry Position
Table 48. Mylan Company Profile and Main Business
Table 49. Mylan Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 50. Mylan Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 51. Mylan Recent Developments
Table 52. Zydus Pharmaceuticals Company Information, Head Office, Market Area and Industry Position
Table 53. Zydus Pharmaceuticals Company Profile and Main Business
Table 54. Zydus Pharmaceuticals Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 55. Zydus Pharmaceuticals Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 56. Zydus Pharmaceuticals Recent Developments
Table 57. Wockhardt Company Information, Head Office, Market Area and Industry Position
Table 58. Wockhardt Company Profile and Main Business
Table 59. Wockhardt Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 60. Wockhardt Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 61. Wockhardt Recent Developments
Table 62. Sun Pharmaceutical Company Information, Head Office, Market Area and Industry Position
Table 63. Sun Pharmaceutical Company Profile and Main Business
Table 64. Sun Pharmaceutical Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 65. Sun Pharmaceutical Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 66. Sun Pharmaceutical Recent Developments
Table 67. Glenmark Pharmaceuticals Ltd. Company Information, Head Office, Market Area and Industry Position
Table 68. Glenmark Pharmaceuticals Ltd. Company Profile and Main Business
Table 69. Glenmark Pharmaceuticals Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 70. Glenmark Pharmaceuticals Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 71. Glenmark Pharmaceuticals Ltd. Recent Developments
Table 72. TRB Pharma S.A. Company Information, Head Office, Market Area and Industry Position
Table 73. TRB Pharma S.A. Company Profile and Main Business
Table 74. TRB Pharma S.A. Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 75. TRB Pharma S.A. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 76. TRB Pharma S.A. Recent Developments
Table 77. Kunming Jida Pharmaceutical Co., Ltd. Company Information, Head Office, Market Area and Industry Position
Table 78. Kunming Jida Pharmaceutical Co., Ltd. Company Profile and Main Business
Table 79. Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 80. Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 81. Kunming Jida Pharmaceutical Co., Ltd. Recent Developments
Table 82. Medzeel Lifescience Company Information, Head Office, Market Area and Industry Position
Table 83. Medzeel Lifescience Company Profile and Main Business
Table 84. Medzeel Lifescience Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 85. Medzeel Lifescience Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 86. Medzeel Lifescience Recent Developments
Table 87. Wellona Pharma Company Information, Head Office, Market Area and Industry Position
Table 88. Wellona Pharma Company Profile and Main Business
Table 89. Wellona Pharma Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 90. Wellona Pharma Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 91. Wellona Pharma Recent Developments
Table 92. Niksan Pharmaceutical Company Information, Head Office, Market Area and Industry Position
Table 93. Niksan Pharmaceutical Company Profile and Main Business
Table 94. Niksan Pharmaceutical Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 95. Niksan Pharmaceutical Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 96. Niksan Pharmaceutical Recent Developments
Table 97. Lunan Pharmaceutical Group Corporation Company Information, Head Office, Market Area and Industry Position
Table 98. Lunan Pharmaceutical Group Corporation Company Profile and Main Business
Table 99. Lunan Pharmaceutical Group Corporation Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 100. Lunan Pharmaceutical Group Corporation Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 101. Lunan Pharmaceutical Group Corporation Recent Developments
Table 102. Zhejiang Xianju Pharmaceutical Co.,Ltd. Company Information, Head Office, Market Area and Industry Position
Table 103. Zhejiang Xianju Pharmaceutical Co.,Ltd. Company Profile and Main Business
Table 104. Zhejiang Xianju Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 105. Zhejiang Xianju Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 106. Zhejiang Xianju Pharmaceutical Co.,Ltd. Recent Developments
Table 107. Hunan Jiudian Pharmaceutical Co.,Ltd. Company Information, Head Office, Market Area and Industry Position
Table 108. Hunan Jiudian Pharmaceutical Co.,Ltd. Company Profile and Main Business
Table 109. Hunan Jiudian Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 110. Hunan Jiudian Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 111. Hunan Jiudian Pharmaceutical Co.,Ltd. Recent Developments
Table 112. Chengdu Brilliant Pharmaceutical Co., Ltd. Company Information, Head Office, Market Area and Industry Position
Table 113. Chengdu Brilliant Pharmaceutical Co., Ltd. Company Profile and Main Business
Table 114. Chengdu Brilliant Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 115. Chengdu Brilliant Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 116. Chengdu Brilliant Pharmaceutical Co., Ltd. Recent Developments
Table 117. Guangdong Eashu Pharmaceutical Co.,Ltd. Company Information, Head Office, Market Area and Industry Position
Table 118. Guangdong Eashu Pharmaceutical Co.,Ltd. Company Profile and Main Business
Table 119. Guangdong Eashu Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Models, Specifications and Application
Table 120. Guangdong Eashu Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Revenue and Gross Margin, 2018-2023
Table 121. Guangdong Eashu Pharmaceutical Co.,Ltd. Recent Developments
List of Figure
Figure 1. Benign Prostatic Hyperplasia Drugs Picture
Figure 2. Global Benign Prostatic Hyperplasia Drugs Industry Market Size and Forecast (US$ million) & (2018-2029)
Figure 3. China Benign Prostatic Hyperplasia Drugs Revenue and Forecast (US$ million) & (2018-2029)
Figure 4. 2018-2029 China Benign Prostatic Hyperplasia Drugs Market Share of Global
Figure 5. Global Benign Prostatic Hyperplasia Drugs Key Participants, Market Share, 2021 VS 2022 VS 2023
Figure 6. Global Benign Prostatic Hyperplasia Drugs Market Share by Company, (Tier 1, Tier 2 and Tier 3), 2018-2023
Figure 7. China Benign Prostatic Hyperplasia Drugs Key Participants, Market Share, 2021 VS 2022 VS 2023
Figure 8. China Benign Prostatic Hyperplasia Drugs Revenue, Domestic VS Import Products, Proportion of China Local Players and Foreign Players, 2018-2023
Figure 9. Benign Prostatic Hyperplasia Drugs Industry Chain
Figure 10. Tamsulosin
Figure 11. Finasteride
Figure 12. Terazosin
Figure 13. Other
Figure 14. By Type, Global Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029, US$ Million
Figure 15. By Type, Global Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2029
Figure 16. Hospital
Figure 17. Clinic
Figure 18. Other
Figure 19. By Application, Global Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029, US$ Million
Figure 20. By Application, Global Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2029
Figure 21. By Region, Global Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2029
Figure 22. North America Benign Prostatic Hyperplasia Drugs Revenue & Forecasts, 2018-2029, US$ Million
Figure 23. By Country, North America Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2023
Figure 24. Europe Benign Prostatic Hyperplasia Drugs Revenue & Forecasts, 2018-2029, US$ Million
Figure 25. By Country, Europe Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2023
Figure 26. Asia Pacific Benign Prostatic Hyperplasia Drugs Revenue & Forecasts, 2018-2029, US$ Million
Figure 27. By Country/Region, Asia Pacific Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2023
Figure 28. South America Benign Prostatic Hyperplasia Drugs Revenue & Forecasts, 2018-2029, US$ Million
Figure 29. By Country, South America Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2023
Figure 30. Middle East & Africa Benign Prostatic Hyperplasia Drugs Revenue & Forecasts, 2018-2029, US$ Million
Figure 31. U.S. Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029, (US$ Million)
Figure 32. By Company, U.S. Benign Prostatic Hyperplasia Drugs Market Share, 2018-2023
Figure 33. By Type, U.S. Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 34. By Application, U.S. Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 35. Europe Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029, (US$ Million)
Figure 36. By Company, Europe Benign Prostatic Hyperplasia Drugs Market Share, 2018-2023
Figure 37. By Type, Europe Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 38. By Application, Europe Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 39. China Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029, (US$ Million)
Figure 40. By Company, China Benign Prostatic Hyperplasia Drugs Market Share, 2018-2023
Figure 41. By Type, China Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 42. By Application, China Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 43. Japan Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029, (US$ Million)
Figure 44. By Company, Japan Benign Prostatic Hyperplasia Drugs Market Share, 2018-2023
Figure 45. By Type, Japan Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 46. By Application, Japan Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 47. South Korea Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029, (US$ Million)
Figure 48. By Company, South Korea Benign Prostatic Hyperplasia Drugs Market Share, 2018-2023
Figure 49. By Type, South Korea Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 50. By Application, South Korea Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 51. Southeast Asia Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029, (US$ Million)
Figure 52. By Company, Southeast Asia Benign Prostatic Hyperplasia Drugs Market Share, 2018-2023
Figure 53. By Type, Southeast Asia Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 54. By Application, Southeast Asia Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 55. India Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029, (US$ Million)
Figure 56. By Company, India Benign Prostatic Hyperplasia Drugs Market Share, 2018-2023
Figure 57. By Type, India Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 58. By Application, India Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 59. Middle East & Asia Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029, (US$ Million)
Figure 60. By Company, Middle East & Asia Benign Prostatic Hyperplasia Drugs Market Share, 2018-2023
Figure 61. By Type, Middle East & Asia Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 62. By Application, Middle East & Asia Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2022 VS 2029
Figure 63. Research Methodology
Figure 64. Breakdown of Primary Interviews
Figure 65. Bottom-up Approaches
Figure 66. Top-down Approaches
Research Methodology:
Global Benign Prostatic Hyperplasia Drugs Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|